Terms: = Prostate cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Prognosis
5 results:
1. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in prostate cancer.
Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
Front Immunol; 2022; 13():777724. PubMed ID: 35154101
[TBL] [Abstract] [Full Text] [Related]
2. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract] [Full Text] [Related]
3. The Immune Landscape of prostate cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract] [Full Text] [Related]
4. Discovery and characterization of long intergenic non-coding RNAs (lincRNA) module biomarkers in prostate cancer: an integrative analysis of RNA-Seq data.
Cui W; Qian Y; Zhou X; Lin Y; Jiang J; Chen J; Zhao Z; Shen B
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S3. PubMed ID: 26100580
[TBL] [Abstract] [Full Text] [Related]
5. [Replacement of the vertebral body with an expansion implant (Synex)].
Krbec M; Stulík J; Tichý V
Acta Chir Orthop Traumatol Cech; 2002; 69(3):158-62. PubMed ID: 12125217
[TBL] [Abstract] [Full Text] [Related]
